HCA Healthcare Valuation
Is HCA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HCA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HCA * (MX$5178.31) is trading below our estimate of fair value (MX$5571.46)
Significantly Below Fair Value: HCA * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HCA *?
Other financial metrics that can be useful for relative valuation.
What is HCA *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$82.37b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.9x |
Enterprise Value/EBITDA | 9.8x |
PEG Ratio | 2.5x |
Price to Earnings Ratio vs Peers
How does HCA *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 27.6x | ||
MEDICA B Médica Sur. de | 8.2x | 9.5% | Mex$4.4b |
4013 Dr. Sulaiman Al Habib Medical Services Group | 53.7x | 13.9% | ر.س109.6b |
300015 Aier Eye Hospital Group | 34.5x | 18.2% | CN¥122.0b |
UHS Universal Health Services | 14x | 8.2% | US$11.2b |
HCA * HCA Healthcare | 15.1x | 6.0% | Mex$82.4b |
Price-To-Earnings vs Peers: HCA * is good value based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (27.7x).
Price to Earnings Ratio vs Industry
How does HCA *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: HCA * is good value based on its Price-To-Earnings Ratio (15.1x) compared to the Global Healthcare industry average (21.5x).
Price to Earnings Ratio vs Fair Ratio
What is HCA *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 15.1x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HCA *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$5,178.31 | Mex$5,847.78 +12.9% | 6.8% | Mex$6,433.56 | Mex$4,850.70 | n/a | 23 |
Apr ’25 | Mex$5,475.92 | Mex$5,611.32 +2.5% | 6.1% | Mex$6,283.95 | Mex$4,737.90 | n/a | 23 |
Mar ’25 | n/a | Mex$5,649.13 0% | 7.9% | Mex$6,341.91 | Mex$4,273.53 | n/a | 22 |
Feb ’25 | n/a | Mex$5,420.01 0% | 10.0% | Mex$6,151.14 | Mex$4,271.63 | n/a | 20 |
Jan ’25 | n/a | Mex$4,942.07 0% | 8.2% | Mex$5,802.75 | Mex$4,291.98 | n/a | 21 |
Dec ’24 | Mex$4,352.94 | Mex$4,849.38 +11.4% | 6.2% | Mex$5,425.84 | Mex$4,306.23 | n/a | 21 |
Nov ’24 | Mex$4,032.82 | Mex$5,141.12 +27.5% | 6.0% | Mex$5,686.85 | Mex$4,585.59 | n/a | 21 |
Oct ’24 | Mex$4,371.03 | Mex$5,433.05 +24.3% | 6.9% | Mex$5,994.14 | Mex$4,452.79 | n/a | 21 |
Sep ’24 | n/a | Mex$5,436.26 0% | 6.7% | Mex$5,984.16 | Mex$4,445.38 | n/a | 22 |
Aug ’24 | n/a | Mex$5,290.28 0% | 6.9% | Mex$5,838.49 | Mex$4,337.16 | n/a | 22 |
Jul ’24 | n/a | Mex$5,386.42 0% | 6.9% | Mex$5,991.83 | Mex$4,451.07 | n/a | 22 |
Jun ’24 | n/a | Mex$5,491.40 0% | 6.8% | Mex$6,180.93 | Mex$4,591.55 | n/a | 22 |
May ’24 | Mex$5,086.00 | Mex$5,519.83 +8.5% | 7.6% | Mex$6,292.97 | Mex$4,674.77 | n/a | 22 |
Apr ’24 | Mex$4,627.31 | Mex$5,171.51 +11.8% | 6.5% | Mex$5,707.07 | Mex$4,399.97 | Mex$5,475.92 | 22 |
Mar ’24 | n/a | Mex$5,171.51 0% | 6.5% | Mex$5,707.07 | Mex$4,399.97 | n/a | 22 |
Feb ’24 | Mex$4,780.00 | Mex$5,158.02 +7.9% | 7.0% | Mex$5,772.51 | Mex$4,375.94 | n/a | 22 |
Jan ’24 | Mex$4,646.00 | Mex$4,853.39 +4.5% | 8.4% | Mex$5,594.90 | Mex$4,245.08 | n/a | 21 |
Dec ’23 | Mex$4,564.00 | Mex$4,712.92 +3.3% | 6.7% | Mex$5,502.09 | Mex$4,218.91 | Mex$4,352.94 | 22 |
Nov ’23 | n/a | Mex$4,736.36 0% | 6.6% | Mex$5,580.73 | Mex$4,239.78 | Mex$4,032.82 | 22 |
Oct ’23 | Mex$3,805.56 | Mex$4,823.55 +26.8% | 10.6% | Mex$5,712.61 | Mex$3,027.89 | Mex$4,371.03 | 23 |
Sep ’23 | n/a | Mex$4,704.94 0% | 11.9% | Mex$5,627.85 | Mex$2,982.96 | n/a | 22 |
Aug ’23 | Mex$4,271.00 | Mex$4,722.50 +10.6% | 13.1% | Mex$5,765.81 | Mex$3,056.09 | n/a | 24 |
Jul ’23 | n/a | Mex$4,918.02 0% | 12.6% | Mex$6,195.18 | Mex$3,036.86 | n/a | 24 |
Jun ’23 | Mex$4,575.50 | Mex$4,960.43 +8.4% | 11.4% | Mex$6,052.62 | Mex$2,966.97 | n/a | 23 |
May ’23 | Mex$4,374.00 | Mex$5,232.29 +19.6% | 12.5% | Mex$6,243.13 | Mex$3,060.36 | Mex$5,086.00 | 22 |
Apr ’23 | n/a | Mex$5,617.78 0% | 11.6% | Mex$6,232.27 | Mex$3,015.62 | Mex$4,627.31 | 23 |
Analyst Forecast: Target price is less than 20% higher than the current share price.